With rigorous economic research and practical policy solutions, we focus on the issues and institutions that are critical to global development. Explore our core themes and topics to learn more about our work.
In timely and incisive analysis, our experts parse the latest development news and devise practical solutions to new and emerging challenges. Our events convene the top thinkers and doers in global development.
Health financing and payment, results-based financing, social protection, conditional cash transfer programs, noncommunicable disease, maternal and child health
Amanda Glassman is chief operating officer and senior fellow at the Center for Global Development and also serves as secretary of the board. Her research focuses on priority-setting, resource allocation and value for money in global health, as well as data for development. Prior to her current position, she served as director for global health policy at the Center from 2010 to 2016, and has more than 25 years of experience working on health and social protection policy and programs in Latin America and elsewhere in the developing world.
Prior to joining CGD, Glassman was principal technical lead for health at the Inter-American Development Bank, where she led policy dialogue with member countries, designed the results-based grant program Salud Mesoamerica 2015 and served as team leader for conditional cash transfer programs such as Mexico’s Oportunidades and Colombia’s Familias en Accion. From 2005-2007, Glassman was deputy director of the Global Health Financing Initiative at Brookings and carried out policy research on aid effectiveness and domestic financing issues in the health sector in low-income countries. Before joining the Brookings Institution, Glassman designed, supervised and evaluated health and social protection loans at the Inter-American Development Bank and worked as a Population Reference Bureau Fellow at the US Agency for International Development. Glassman holds a MSc from the Harvard School of Public Health and a BA from Brown University, has published on a wide range of health and social protection finance and policy topics, and is editor and coauthor of the books Millions Saved: New Cases of Proven Success in Global Health (Center for Global Development 2016), From Few to Many: A Decade of Health Insurance Expansion in Colombia (IDB and Brookings 2010), and The Health of Women in Latin America and the Caribbean (World Bank 2001).
Here, CGD experts Amanda Glassman, Scott Morris, and Jeremy Konyndyk weigh in on some of the key points we heard (and live tweeted) during Secretary Tillerson’s testimony before the Senate Foreign Relations Committee and, later, when he answered questions from the Senate Appropriations Subcommittee on State, Foreign Operations, and Related Programs.
As a new WHO Director-General—Dr. Tedros Adhanom Ghebreyesus—prepares to take office, many have called for clearer priorities, governance and organizational reforms, and funding expansions. All good, but there is one additional, grossly neglected issue that requires urgent action: WHO needs better economic advice. As I explain in this blogpost, that should come in the form of appointing WHO’s own chief economist.
Please join us to celebrate the launch of Charles Kenny's latest book, Results Not Receipts: Counting the Right Things in Aid and Corruption. This work illustrates a growing problem: an important and justified focus on corruption as a barrier to development has led to policy change in aid agencies that is damaging the potential for aid to deliver results. Donors have treated corruption as an issue they can measure and improve, and from which they can insulate their projects at acceptable costs by controlling processes and monitoring receipts. Results Not Receipts highlights the weak link between donors’ preferred measures of corruption and development outcomes related to our limited ability to measure the problem. It discusses the costs of the standard anti-corruption tools of fiduciary controls and centralized delivery, and it suggests a different approach to tackling the problem of corruption in development: focus on outcomes.
Consider this statement: Science knows how to deal with a pandemic outbreak, but policy gets in the way. That was how we framed a recent event at CGD with key people who led the US government’s response to the Ebola outbreak in 2014. Drawing from that event, this podcast brings you some ideas of how to improve the global system of response and increase our preparedness for the next inevitable outbreak. Speakers include Jeremy Konyndyk, Amy Pope, David Smith, Rebecca Martin, and Amanda Glassman.
An infectious disease outbreak anywhere on earth poses a direct threat to Americans. On airplanes, trains, and ships—and via migratory birds or insects that cannot be constrained by borders—pathogens can easily travel around the world, reaching a network of major cities in as little as 36 hours. Keeping Americans safe from the pandemic threat will require U.S. action and leadership both at home and abroad.
This paper examines opportunities for improved efficiency in malaria control, analyzing the effectiveness of interventions and current trends in spending. Overall, it appears that resources for malaria control are well spent—however, there remain areas for improved efficiency, including (i) improving procurement procedures for bed nets, (ii) developing efficient ways to replace bed nets as they wear out, (iii) reducing overlap of spraying and bed net programs, (iv) expanding the use of rapid diagnostics, and (v) scaling up intermittent presumptive treatment for pregnant women and infants.
The United States Government has the requisite technical know-how, financial and logistical resources, and bipartisan political support to lead the response to enduring global health challenges, and it is critical that the United States is prepared to meet them. This memo’s six recommendations are the result of a roundtable discussion on how the next administration and Congress can update and improve on the US global health engagement model.
The New England Journal of Medicine recently published the results of “the Oregon experiment” based on the 2008 US Medicaid program expansion in Oregon. The study is one of very few randomized control trials on publicly-subsidized health insurance that exists to guide health policy, and found what some commentators considered a disappointing result: while health care utilization increased and households were protected from financial hardship, expanding Medicaid coverage had “no significant impact on measured physical health outcomes over a 2-year period.”